Dianna Douglass
Psychiatric/Mental Health · Oxford, MSNPI 1043679079
Payments from drug & device makers
Across 119 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$500
- AbbVie$455
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$227
- Johnson & Johnson$203
- Teva Pharmaceuticals USA, Inc.$178
- Supernus Pharmaceuticals, Inc.$174
- plus $526 from 13 others
What the payments were for
- Food & beverage$2,12194%
- Education$1416%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 25 | $500 |
| AbbVie(2 entities) | 26 | $455 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $227 |
| Johnson & Johnson | 10 | $203 |
| Teva Pharmaceuticals USA, Inc. | 5 | $178 |
| Supernus Pharmaceuticals, Inc. | 9 | $174 |
| Axsome Therapeutics, Inc. | 7 | $153 |
| Corium, LLC | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $54 |
| Lundbeck LLC | 2 | $39 |
| Tris Pharma Inc | 2 | $30 |
| Bioxcel Therapeutics, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Indivior Inc. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
How this compares
$2,262 in reported general payments places this provider in the 75th percentile of 486 psychiatric/mental health providers in Mississippi.
See all psychiatric/mental health providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 24 | $1,139 |
| Quetiapine Fumarate | 25 | $944 |
| Lamotrigine ErLamotrigine | 15 | $886 |
| Bupropion Hcl SrBupropion Hcl | 21 | $346 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 25 | $307 |
| Bupropion XlBupropion Hcl | 24 | $297 |
| Lamotrigine | 33 | $255 |
| Buspirone Hcl | 14 | $119 |
| Sertraline Hcl | 20 | $64 |
| Escitalopram Oxalate | 12 | $44 |
| Lorazepam | 19 | $42 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Oxford
- Ashley KarelVicksburg$129K
- Amanda HamCorinth$64K
- Alanna WrightJackson$58K
- Amanda ThomasTupelo$41K
- Amelia KelleyMeridian$38K
- Belinda EdwardsJackson$29K
- Lawanda GlassCleveland$22K
- Rebecca HartzogHattiesburg$17K
- Leigh CalcoteHattiesburg$15K
- Rose CliffordGautier$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.